GlassScriptPhysician profile
Jessy Samuel
NPI 1154940450
$1,099.96
in general payments reported to CMS, 2019-2025
18 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.24 · 2022: $254 · 2023: $342 · 2024: $199 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.83 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $154.42 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $140.27 | 2023-2024 | Quviviq |
| Abbvie INC. | $125.00 | 2022 | |
| Almatica Pharma LLC | $124.55 | 2021-2025 | Loreev Xr |
| Pfizer INC. | $66.73 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $64.68 | 2023-2025 | Seglentis, Zoryve |
| Lilly USA, LLC | $54.33 | 2021-2023 | Mounjaro |
| Novo Nordisk INC | $34.73 | 2023-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.01 | 2022-2024 | Xifaxan |
| Exact Sciences Corporation | $26.03 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $18.75 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.66 | 2023 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $17.92 | 2023 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.49 | 2024 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $13.76 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.64 | 2024 | Edarbi |
| Eisai INC. | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessy Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.